← Back to Home

Estimating Recurrence Risk from Breast MRI: TumorSight Risk Receives FDA Clearance

The software integrates imaging, pathology, and clinical data to provide five- and ten-year prognostic information for certain patients with breast cancer. A retrospective validation involving 2,129 patients showed an ability to stratify risk, but whether this can improve treatment outcomes remains a separate question.

By SURL BioNews

After a breast cancer diagnosis, treatment planning presents another challenge: how can the likelihood of future recurrence be estimated so that treatment intensity more closely matches an individual’s risk? SimBioSys announced on October 15 that TumorSight Risk, which integrates breast magnetic resonance imaging (MRI), pathology, and clinical data, had received clearance from the U.S. Food and Drug Administration (FDA), giving images obtained during care an additional use in assessing long-term prognosis.

FDA records show that this Class II medical device received a determination of substantial equivalence through the 510(k) process on September 25, before the company’s announcement. It is intended for adult women diagnosed with hormone receptor-positive (HR+), HER2-negative, stage I to IIIA breast cancer, with N0 or N1 lymph node status. It provides adjunctive prognostic information that must be interpreted alongside other clinical and pathological factors.

The software uses pretreatment dynamic contrast-enhanced MRI, with the existing TumorSight Viz system identifying different tissues. It then combines imaging features with data such as age, tumor stage, lymph node status, and histological grade to generate a prognostic score from 0 to 100 and estimates of five- and ten-year recurrence risk. Scores of 20 or below are classified as low risk, scores above 20 through 35 as intermediate risk, and scores above 35 as high risk; the score itself is not a recurrence probability.

The clinical validation supporting clearance included 2,129 patients from four U.S. medical institutions and retrospectively analyzed existing images, medical records, and recurrence data. According to the FDA’s public summary, estimated ten-year recurrence rates for the low-, intermediate-, and high-risk groups were 8.6%, 13.4%, and 26.4%, respectively. The company separately reported that the high-risk group had approximately 3.3 times the recurrence risk of the low-risk group; this relative risk result and each group’s cumulative recurrence rate at a specified time point are different statistical presentations.

The practical appeal of this approach lies in using images already obtained to supplement risk information. The company said results can be provided before surgery and do not require additional tissue shipments. However, use still depends on the availability of suitable MRI data; the clearance documents list compatible equipment as GE and Siemens 1.5T and 3T systems, so compatibility cannot simply be assumed for images from all hospitals.

The validation results support the software’s ability to distinguish groups with different prognoses, but they have yet to answer whether adjusting treatment based on the scores can reduce recurrence, reduce unnecessary treatment, or improve quality of life. A retrospective study also cannot directly establish that a particular score predicts the benefit of chemotherapy or extended endocrine therapy. This clearance opens up clinical applications for imaging-assisted prognostic assessment, while its actual value still needs to be tested through patient outcomes in subsequent care.

References

  1. SimBioSys
  2. U.S. Food and Drug Administration
  3. U.S. Food and Drug Administration